Daiichi Sankyo's revenue rose 19.7% to ¥1.167 trillion in the six months ended 30 September 2026, according to financial results released on 30 October. Reported operating profit increased 34.4% to ¥193.795 billion.
Core operating profit grew faster, rising 46.9% to ¥221.331 billion. The company changed the definition of that adjusted measure for the fiscal year ending March 2027 and recast the comparison shown in its table.
Six-month results, not a standalone quarter
Exact primary source checked at 2026-10-31T09:00:45.525Z. Amounts and periods are as labelled below.
| Measure or condition | Verified observation | Primary evidence |
|---|---|---|
| Reporting period | 1 April–30 September 2026; cumulative six months | Daiichi Sankyo Company, Limited |
| Revenue | ¥1,167.233bn; +19.7% | Daiichi Sankyo Company, Limited |
| Reported operating profit | ¥193.795bn; +34.4% | Daiichi Sankyo Company, Limited |
| Core operating profit | ¥221.331bn; +46.9% | Daiichi Sankyo Company, Limited |
| Profit attributable to owners | ¥151.534bn; +15.8% | Daiichi Sankyo Company, Limited |
| Basic EPS | ¥83.22 versus ¥70.55 | Daiichi Sankyo Company, Limited |
Why the core figure is higher
Core operating profit excludes specified non-core income and expenses from reported operating profit. Under the revised definition, the exclusions include product-related intangible amortisation, restructuring, impairments, settlements and acquisition-related costs, among other items described by the company.
The issuer says the prior-period core figures in the comparison table also reflect the definition change. Readers should use that recast series rather than comparing the latest core profit with an older, differently defined figure. Reported operating profit remains a separate accounting measure.
The main reading traps
Although the materials are labelled FY2026 Q2, the headline income statement covers April through September. It is therefore misleading to call ¥1.167 trillion revenue for only July–September. The annual fiscal-year label also differs from a calendar-year quarter.
Daiichi Sankyo linked sales growth to its main products and favourable foreign-exchange effects. That explanation does not mean every medicine, region or margin improved. The useful next check is the detailed revenue breakdown and profit reconciliation, with no inference of guaranteed product approvals, future sales or investment returns.
Primary source record
Daiichi Sankyo Company, Limited — https://www.daiichisankyo.com/files/investors/library/quarterly_result/2026/FY2026Q2_Financial_Results_E.pdf; observed 2026-10-31T09:00:45.525Z. This is primary-source checking assisted by AI, not independent human editorial approval.
Additional primary record
Daiichi Sankyo Company, Limited — https://www.daiichisankyo.com/investors/library/quarterly_result/; checked 2026-10-31T09:07:00.284Z. Official IR financial-results library linking the exact FY2026Q2 PDF and related materials; same issuer, not independent confirmation.
Recorded source observation: . This is a source-check timestamp, not a market quote or a new article update.